Prospecto: information for the patient
Vaborem 1g/1g powder for concentrate for solution for infusion
meropenem/vaborbactam
Read this prospect carefully before starting to use this medication, because it contains important information for you.
1.What is Vaborem and for what it is used
2.What you need to know before starting to receive Vaborem
3.How you will be administered Vaborem
4.Possible adverse effects
5.Storage of Vaborem
6.Contents of the package and additional information
What is Vaborem
Vaborem is an antibiotic that contains two active principles: meropenem and vaborbactam.
How Vaborem is used
Vaborem is used in adults to treat certain severe bacterial infections:
It is also used to treat infections:
You should not receive Vaborem if
Warnings and precautions
Consult your doctor or nurse before starting to receive Vaborem if:
If any of the above concerns you or if you are unsure, speak with your doctor or nurse before using Vaborem.
You may develop signs and symptoms of severe skin reactions (see section 4). If this happens, inform your doctor or nurse immediately so that they can treat the symptoms.
Speak with your doctor or nurse if you experience diarrhea during treatment.
This medication may affect the liver. Your doctor may take a blood sample to check how your liver is functioning while you are taking the medication.
New infection
Although Vaborem may combat certain bacteria, there is a possibility that you may develop a new infection caused by another microorganism during or after treatment. Your doctor will closely monitor you to detect any new infection and will give you another treatment if necessary.
Blood tests
If you are to undergo any blood tests, inform your doctor that you are taking Vaborem, as it may give an abnormal result with a test called the "Coombs test". The results of this test show the presence of antibodies that may destroy red blood cells or may be affected by your immune system's response to Vaborem.
Children or adolescents
Vaborem should not be used in children or adolescents under 18 years of age, as its safety in these age groups is unknown.
Other medications and Vaborem
Inform your doctor if you are using, have used recently, or may need to use any other medication.
It is especially important to inform your doctor if you are taking any of the following medications:
If any of the above concerns you, inform your doctor before using Vaborem.
If you are pregnant, think you may be pregnant, or intend to become pregnant, consult your doctor before receiving this medication.
As a precaution, you should not take this medication during pregnancy.
It is essential to inform your doctor if you are breastfeeding or intend to breastfeed before receiving Vaborem. Small amounts of this medication may pass into breast milk and affect the baby. Therefore, you should stop breastfeeding before starting Vaborem treatment.
Driving and operating machinery
Vaborem may make you feel dizzy, drowsy, and lethargic, may give you a headache or a tingling sensation, or, in rare cases, cause a seizure or convulsion. This may affect your ability to drive, use tools, or operate machinery.
Vaborem contains sodium
This medication contains 250mg of sodium (the main component of table salt/for cooking) in each vial. This is equivalent to 12.5% of the maximum daily sodium intake recommended for an adult.
The recommended dose is 2vials (a total of 2g of meropenem and 2gof vaborbactam), administered every 8 hours. Your doctor will decide how many days of treatment are needed, depending on the type of infection.
A doctor or nurse will administer Vaborem via infusion (drip) in a vein over 3 hours.
Patients with kidney problems
If you have kidney problems, your doctor may reduce the dose. Your doctor may want to do some blood tests to see how your kidneys are working.
If you are given too much Vaborem
A doctor or nurse will administer Vaborem, so it is unlikely that you will be given the wrong dose. If you think you have been given too much Vaborem, inform your doctor or nurse immediately.
If you miss a dose of Vaborem
If you think you have missed a dose, inform your doctor or nurse immediately.
If you have any other questions about the use of this medication, ask your doctor or nurse.
Like all medicines, this medicine can cause side effects, although not everyone will experience them.
Severe side effects
If you notice any of the following severe side effects, inform your doctor immediately as you may need urgent treatment:
Other side effects
If you notice any of the following side effects, inform your doctor or nurse:
Frequent:(may affect up to 1 in 10 people)
Less frequent:(may affect up to 1 in 100 people)
Rare:(may affect up to 1 in 1,000 people)
Frequency unknown:(cannot be estimated from available data)
Reporting side effects
If you experience any type of side effect, consult your doctor or nurse, even if it is a possible side effect that does not appear in this leaflet.You can also report them directly through the national reporting system included in theAppendix V. By reporting side effects, you can contribute to providing more information about the safety of this medicine.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the packaging. The expiration date is the last day of the month indicated.
Do not store above 25°C.
Composition of Vaborem
Appearance of the product and contents of the container
Vaborem is a white to light yellow powder for concentrate for solution for infusion supplied in a vial.
Vaborem is available in containers containing 6 vials.
Marketing Authorization Holder
Menarini International Operations Luxembourg S.A.
1, Avenue de la Gare
L-1611, Luxembourg
Luxembourg
Responsible for manufacturing
ACS Dobfar, S.p.A.
Nucleo Industriale S. Atto
(loc. S. Nicolo’ a Tordino)
64100 Teramo (TE)
Italy
For more information about this medicine, please contact the local representative of the
marketing authorization holder:
België/Belgique/Belgien Menarini Benelux NV/SA Tél/Tel: + 32 (0)2 721 4545 | Lietuva UAB “BERLIN-CHEMIE MENARINI BALTIC” Tel: +370 52 691 947 |
?????? ??????-????/?.????????????E??? ???.: +359 24540950 | Luxembourg/Luxemburg Menarini Benelux NV/SA Tél/Tel: + 32 (0)2 721 4545 |
Ceská republika Berlin-Chemie/A.Menarini Ceska republika s.r.o. Tel: +420 267 199 333 | Magyarország Berlin-Chemie/A. Menarini Kft. Tel.: +36 17997320 |
Danmark Menarini International Operations Luxembourg S.A. Tlf:+352 264976 | Malta Menarini International Operations Luxembourg S.A. Tel: +352 264976 |
Deutschland Berlin-Chemie AG Tel: +49 (0) 30 67070 | Nederland Menarini Benelux NV/SA Tel: +32 (0)2 721 4545 |
Eesti OÜ Berlin-Chemie Menarini Eesti Tel: +372 667 5001 | Norge Menarini International Operations Luxembourg S.A. Tlf:+352 264976 |
Ελλ?δα MENARINI HELLAS AE Τηλ: +30 210 8316111-13 | Österreich A. Menarini Pharma GmbH Tel: +43 1 879 95 85-0 |
España Laboratorios Menarini S.A. Tel: +34-93 462 88 00 | Polska Berlin-Chemie/Menarini Polska Sp. z o.o. Tel.: +48 22 566 21 00 |
France MENARINI France Tél: +33 (0)1 45 60 77 20 | Portugal A. Menarini Portugal – Farmacêutica, S.A. Tel: +351 210 935 500 |
Hrvatska Berlin-Chemie Menarini Hrvatska d.o.o. Tel: + 385 1 4821 361 | România Berlin-Chemie A.Menarini S.R.L. Tel: +40 21 232 34 32 |
Ireland A. Menarini Pharmaceuticals Ireland Ltd Tel: +353 1 284 6744 | Slovenija Berlin-Chemie / A. Menarini Distribution Ljubljana d.o.o. Tel: +386 01 300 2160 |
Ísland Menarini International Operations Luxembourg S.A. Sími: +352 264976 | Slovenská republika Berlin-Chemie /A. Menarini Distribution Slovakia s.r.o Tel: +421 2544 30730 |
Italia A. Menarini - Industrie Farmaceutiche Riunite - s.r.l. | Suomi/Finland Berlin-Chemie/A.Menarini Suomi OY Puh/Tel: +358 403 000 760 |
Κ?προς MENARINI HELLAS AE Τηλ: +30 210 8316111-13 | Sverige Pharmaprim ABTel:+46 8355933 |
Latvija SIA Berlin-Chemie/Menarini Baltic Tel: +371 67103210 | United Kingdom (Irlanda del Norte) A. Menarini Farmaceutica Internazionale S.R.L. Tel: +44 (0)1628 856400 |
Last update of this leaflet:07/2023
Other sources of information
The detailed information on this medicine is available on the website of the European Medicines Agencyhttp://www.ema.europa.eu.
------------------------------------------------------------------------------------------------------------------
This information is intended solely for healthcare professionals:
Vaborem is intended for intravenous administration (i.v.), only after reconstitution and dilution.
Use aseptic techniques for the preparation and administration of the solution.
The number of vials used for a single dose will depend on the patient's creatinine clearance (ACr).
Reconstitution:
20ml of 9mg/ml (0.9%) sodium chloride (normal saline) injection solution from a 250ml infusion bag of 9mg/ml (0.9%) sodium chloride injection solution should be withdrawn and used to reconstitute each vial and the appropriate number of vials of meropenem/vaborbactam for the corresponding dose of Vaborem:
After mixing carefully to dissolve, the reconstituted meropenem/vaborbactam solution will have an approximate concentration of 0.05g/ml of meropenem and an approximate concentration of 0.05g/ml of vaborbactam. The final volume is approximately 21.3ml. The reconstituted solution is not for direct injection. The reconstituted solution should be diluted before intravenous infusion.
Dilution:
To prepare the 2g/2g dose of Vaborem for intravenous infusion: immediately after reconstitution of two vials, the contents of each of the two reconstituted vials should be withdrawn and added to a 250ml infusion bag of 9mg/ml (0.9%) sodium chloride injection solution. The final concentration of the infusion of meropenem and vaborbactam will be approximately 8mg/ml each.
To prepare the 1g/1g dose of Vaborem for intravenous infusion: immediately after reconstitution of one vial, the contents of the reconstituted vial should be withdrawn and added to a 250ml infusion bag of 9mg/ml (0.9%) sodium chloride injection solution. The final concentration of the infusion of meropenem and vaborbactam will be approximately 4mg/ml each.
To prepare the 0.5g/0.5g dose of Vaborem for intravenous infusion: immediately after reconstitution of one vial, 10.5ml of the contents of the reconstituted vial should be withdrawn and added to a 250ml infusion bag of 9mg/ml (0.9%) sodium chloride injection solution. The final concentration of the infusion of meropenem and vaborbactam will be 2mg/ml each.
The solution should be visually inspected for particles after dilution. The color of the diluted solution is transparent to light yellow.
After dilution, the infusion should be administered within 4hours if stored at 25°C, or within 22hours if refrigerated at 2–8°C.
From a microbiological point of view, the medicinal product should be used immediately after reconstitution and dilution.
Vaborem is not chemically compatible with solutions containing glucose. This medicinal product should not be mixed with other products, except those mentioned in section 6.6 of the SmPC.
Have questions about this medication or your symptoms? Connect with a licensed doctor for guidance and personalized care.